REGULATORY
Japan’s 1st Sakigake-Designated Oncolytic Virus Up for Advisory Panel Review on May 24
A key Japanese health ministry panel will review whether to back approval of Daiichi Sankyo’s sakigake-designated oncolytic virus G47∆ (teserpaturev) on May 24 for an indication of malignant glioma. A number of companies are developing oncolytic viruses, and teserpaturev is…
To read the full story
REGULATORY
- LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
- MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
- Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
- Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





